Paris-based Exeliom Biosciences completes final close of €24 million Series A to further progress its microbiome-based inmunotherapy
Published on July 3, 2023
Exeliom Biosciences, a clinical-stage biopharmaceutical company specialized in the development of microbiome-based immunotherapies with a mission to bring innovation to the treatment of inflammatory bowel diseases, cancer, and infectious diseases, announced today the completion of its €24 million Series A to progress the clinical development of its therapeutic pipeline, including several clinical trials of EXL01,…
The post Paris-based Exeliom Biosciences completes final close of €24 million Series A to further progress its microbiome-based inmunotherapy appeared first on EU-Startups.